Adverse events of targeted therapies approved for women's cancers
Mathilde Saint-Ghislain1, Chloé Levenbruck2, Audrey Bellesoeur1,2,3
1Medical Oncology Department, Institut Curie, Paris, France.
Abstract:
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle inhibitors for hormone receptor positive breast cancer, antibody drug conjugate for human epidermal growth factor receptor 2 positive and triple negative breast cancer, and poly-ADP-ribose polymerase inhibitors for ovarian cancer. This article focuses first on the challenges for health care systems to address the specificities of each emerging targeted therapy and new issues raised by oral antitumor treatments, including individualization of prescriptions, drug-drug interaction assessment, pharmaceutical counseling, patient education, and outpatient management. Then, we provide an overview of the main adverse effects of targeted therapies approved for breast and gynecologic cancers, such as hematologic toxicity of cyclin-dependent kinase 4/6 inhibitors and poly-ADP-ribose polymerase inhibitors, metabolic disorders of phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin inhibitors, and cardiovascular toxicity of agents targeting human epidermal growth factor receptor 2.
Insights
Precision medicine advances offer new targeted therapies for breast and gynecologic cancers. This review details their challenges, adverse effects, and management for healthcare systems and patients.
Area of Science:
- Oncology
- Pharmacology
- Healthcare Management
Background:
- Breast and gynecologic cancers impact millions of women globally.
- Recent advances in precision medicine have led to new targeted therapies.
- Emerging treatments include cell cycle inhibitors, antibody drug conjugates, and PARP inhibitors.
Purpose of the Study:
- To address challenges in healthcare systems for emerging targeted therapies.
- To outline adverse effects of novel treatments for breast and gynecologic cancers.
- To discuss management strategies for oral antitumor treatments.
Main Methods:
- Review of recent targeted therapies for breast and gynecologic cancers.
- Analysis of healthcare system challenges and patient management issues.
- Overview of main adverse effects associated with targeted therapies.
Main Results:
- New therapeutic classes require specific healthcare system adaptations.
- Oral antitumor treatments present challenges in prescription, interactions, and patient education.
- Key adverse effects include hematologic, metabolic, and cardiovascular toxicities.
Conclusions:
- Healthcare systems must adapt to the complexities of targeted cancer therapies.
- Effective management of adverse events is crucial for patient outcomes.
- Individualized patient care and education are essential for emerging cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:10Drugs that Destabilize Microtubules
01:24Disorders of the Female Reproductive System